Home / Health / Lilly Warns: Compounded Drugs Hide Unknown Dangers
Lilly Warns: Compounded Drugs Hide Unknown Dangers
12 Mar
Summary
- Unknown impurity found in compounded weight-loss drugs.
- Eli Lilly warns of potential health risks to consumers.
- Company calls for nationwide recall of mixed medications.
Eli Lilly has issued a significant public health warning concerning compounded weight-loss medications. The U.S. drugmaker revealed that an unidentified impurity, resulting from the preparation process, has been detected in products containing both vitamin B12 and the active ingredient of its Zepbound medication. This impurity was present in all ten samples tested by Lilly.
The company highlighted that "nothing is known about its short- or long-term effects in humans, the potential impact on the drug's interaction with the GLP-1 and GIP receptors, toxicity, immune reactions, or how it is absorbed, distributed, metabolized, and eliminated." Lilly has alerted the U.S. Food and Drug Administration (FDA) and is advocating for a nationwide recall.
This alert is part of Lilly's broader campaign against drug compounders accused of selling unapproved versions of Zepbound and Mounjaro, both containing tirzepatide. The FDA previously warned telehealth companies about misleading claims regarding compounded drugs, emphasizing their inherent risks due to a lack of safety and effectiveness reviews.
